Roche to deliver 178 million COVID-19 rapid antigen tests in support of the Taiwan government’s pandemic management program

Taipei--- Roche Diagnostics Taiwan today announced that, in support of the Taiwan government’s pandemic management program and enable rapid COVID-19 self-testing, it has completed the initial supply of 70 million kits of the SARS-CoV-2 Antigen Self Test Nasal. It also announced that a further 108 million self-tests will be supplied and are scheduled to arrive in the coming weeks.

“We are very grateful to the Central Epidemic Command Center (CECC) for its support, close collaboration and trust. Over the few weeks, our Roche team worked tirelessly with the CECC to make the supply of these self-tests happen,” said Richard Goh, General Manager Roche Diagnostics Taiwan. “We are very humbled to be given the opportunity to partner with the government and contribute to Taiwan’s efforts to combat the pandemic.”

"About 84 million Roche-branded self-test kits should be delivered by the end of May,” said Minister of Health and Welfare Chen Shih-chung, who heads the Central Epidemic Command Center (CECC) Taiwan. "With Roche’s strong commitment and support on the timely arrival, we will be able to continue providing sufficient rapid testing to support the public’s fight against the COVID-19 pandemic in Taiwan."

Roche is deeply committed to supporting the global response to the COVID-19 pandemic.  Roche’s leading portfolio of COVID-19 test solutions covers reliable, high quality tests to deliver effective results such as high-throughput PCR testing, point-of-care PCR testing, antibody testing, and rapid antigen testing to meet different test needs.